Immunogenicity of a DNA vaccine candidate for COVID-19

The effectiveness of a DNA vaccine against SARS-CoV-2 infection was evaluated using mice and guinea pigs. DNA vaccine encoding SARS-CoV-2 spike protein was administrated to the tibialis anterior muscle or skin using the CELLECTRA delivery device to mice or guinea pigs respectively. The effective neutralizing antibodies and T cell responses against SARS-CoV-2 infection was confirmed using in vitro virus infection study. The evaluation of the actual protection efficiency against SARS-CoV-2 infection should be required by using susceptible animal models.